Reckitt, XenoPort enter into licensing deal for arbaclofen placarbil
Under the deal, Reckitt will be granted exclusive worldwide rights for the development and commercialization of XenoPort’s arbaclofen placarbil for all indications. Arbaclofen placarbil is a patent protected
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.